UPC supply chain intelligence for Universe Pharmaceuticals INC: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Universe Pharmaceuticals INC (UPC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ONE-SUPPLIER | ONE-SUPPLIER | 90% | For the fiscal year ended September 30, 2023, one supplier accounted for 29.6% of our total purchases. |
| TWO-SUPPLIERS | TWO-SUPPLIERS | 90% | For the fiscal year ended September 30, 2024, two suppliers accounted for 28.0% and 13.4% of our total purchases, respectively. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CLINICS | CLINICS | 90% | For the fiscal year ended September 30, 2025, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 46.41%, 13.16%, 0.74%, and 39.69% o… |
| DRUGSTORE-CHAINS | DRUGSTORE-CHAINS | 90% | For the fiscal year ended September 30, 2025, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 46.41%, 13.16%, 0.74%, and 39.69% o… |
| HOSPITALS | HOSPITALS | 90% | For the fiscal year ended September 30, 2025, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 46.41%, 13.16%, 0.74%, and 39.69% o… |
| PHARMACEUTICAL-DISTRIBUTORS | PHARMACEUTICAL-DISTRIBUTORS | 90% | For the fiscal year ended September 30, 2025, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 46.41%, 13.16%, 0.74%, and 39.69% o… |
| BEIJING-CO-LTD | BEIJING-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| CHINA-BEIJING-TONG-REN-TANG-GROUP-CO-LTD | CHINA-BEIJING-TONG-REN-TANG-GROUP-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| CO-LTD | CO-LTD | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| FUZI-LIZHONG-PILL-CHINA-BEIJING-TONG-REN-TANG-GR | FUZI-LIZHONG-PILL-CHINA-BEIJING-TONG-REN-TANG-GR | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| GUANGZHOU-BAIYUNSHAN-PHARMACEUTICAL-HOLDINGS-CO- | GUANGZHOU-BAIYUNSHAN-PHARMACEUTICAL-HOLDINGS-CO- | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| GUANGZHOU-PHARMACEUTICAL-CO-LTD | GUANGZHOU-PHARMACEUTICAL-CO-LTD | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| HEALTH-HEADLINE-TECHNOLOGY-CO-LTD | HEALTH-HEADLINE-TECHNOLOGY-CO-LTD | 62% | e fiscal year ended September 30, 2023, we entered into an advertising service agreement with a third-party, Health Headline Technology Co., Ltd. (“Health Headline”), pursuant to which, Health Headli… |
| JIANGXI-CHENYUAN-CONSTRUCTION-PROJECT-CO-LTD | JIANGXI-CHENYUAN-CONSTRUCTION-PROJECT-CO-LTD | 62% | Item 19. EXHIBITS EXHIBIT INDEX Exhibit No. Description 1.1 Amended and Restated Memorandum of Association and Amended and Restated Articles of Association(incorporated by reference to Exhibit 1.1 of… |
| JIANGXI-YUESHANG-INVESTMENT-CO-LTD | JIANGXI-YUESHANG-INVESTMENT-CO-LTD | 62% | Item 19. EXHIBITS EXHIBIT INDEX Exhibit No. Description 1.1 Amended and Restated Memorandum of Association and Amended and Restated Articles of Association(incorporated by reference to Exhibit 1.1 of… |
| JIANGXI-ZHONGYUAN-PHARMACEUTICAL-CO-LTD | JIANGXI-ZHONGYUAN-PHARMACEUTICAL-CO-LTD | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| PHARMACEUTICALS-CO-LTD | PHARMACEUTICALS-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| QUANLU-PILL-RENHE-PHARMACEUTICALS-CO | QUANLU-PILL-RENHE-PHARMACEUTICALS-CO | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| SHENRONG-WEISHENG-PILL-CHINA-BEIJING-TONG-REN-TA | SHENRONG-WEISHENG-PILL-CHINA-BEIJING-TONG-REN-TA | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| SHENYANG-DONGXIN-PHARMACEUTICAL-INDUSTRY-CO-LTD | SHENYANG-DONGXIN-PHARMACEUTICAL-INDUSTRY-CO-LTD | 62% | eement, intellectual property rights in independently developed results vest exclusively with the developing party, while jointly developed results and associated intellectual property rights are sha… |
| SHINVA-MEDICAL-INSTRUMENT-CO-LTD | SHINVA-MEDICAL-INSTRUMENT-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| SUNUNION-HOLDING-GROUP-LIMITED | SUNUNION-HOLDING-GROUP-LIMITED | 62% | ntity in China is also required to further set aside a portion of its after-tax profits to fund the employee welfare fund, although the amount to be set aside, if any, is determined at the discretion… |
| SUPPLY-CO-LTD | SUPPLY-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| UNIVEST-SECURITIES-LLC | UNIVEST-SECURITIES-LLC | 62% | dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments … |
| YUNNAN-BAIYAO-GROUP-CHINA-RESOURCES | YUNNAN-BAIYAO-GROUP-CHINA-RESOURCES | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| ZHONGYUAN-PHARMACEUTICALS-CO-LTD | ZHONGYUAN-PHARMACEUTICALS-CO-LTD | 62% | Zhongyuan Pharmaceuticals Co., Ltd. Competitors of Third-party Products Our competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| UPC-DEBT | Debt stack $2.1B | 90% | Market cache reports total debt of $2.1B. |
| UPC-DEBT-13230 | Warrants outstanding: 0.001 | 90% | xbrl warrant detail from xbrl 2023-03-31. |